329 related articles for article (PubMed ID: 21668859)
1. Immunotherapy concepts under investigation.
Kündig TM
Allergy; 2011 Jul; 66 Suppl 95():60-2. PubMed ID: 21668859
[TBL] [Abstract][Full Text] [Related]
2. Intralymphatic immunotherapy.
Senti G; Johansen P; Kündig TM
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):537-43. PubMed ID: 19680119
[TBL] [Abstract][Full Text] [Related]
3. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy.
von Moos S; Kündig TM; Senti G
Immunol Allergy Clin North Am; 2011 May; 31(2):391-406, xi. PubMed ID: 21530827
[TBL] [Abstract][Full Text] [Related]
4. IVN201--therapy with a construct containing functional fusion peptides.
Rose H
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():319-27; discussion 327-8. PubMed ID: 20799476
[TBL] [Abstract][Full Text] [Related]
5. New routes of allergen immunotherapy.
Aricigil M; Muluk NB; Sakarya EU; Sakalar EG; Senturk M; Reisacher WR; Cingi C
Am J Rhinol Allergy; 2016 Nov; 30(6):193-197. PubMed ID: 28124639
[TBL] [Abstract][Full Text] [Related]
6. Intralymphatic injections as a new administration route for allergen-specific immunotherapy.
Martínez-Gómez JM; Johansen P; Erdmann I; Senti G; Crameri R; Kündig TM
Int Arch Allergy Immunol; 2009; 150(1):59-65. PubMed ID: 19339803
[TBL] [Abstract][Full Text] [Related]
7. Intralymphatic Immunotherapy: Update and Unmet Needs.
Senti G; Freiburghaus AU; Larenas-Linnemann D; Hoffmann HJ; Patterson AM; Klimek L; Di Bona D; Pfaar O; Ahlbeck L; Akdis M; Weinfeld D; Contreras-Verduzco FA; Pedroza-Melendez A; Skaarup SH; Lee SM; Cardell LO; Schmid JM; Westin U; Dollner R; Kündig TM
Int Arch Allergy Immunol; 2019; 178(2):141-149. PubMed ID: 30391954
[TBL] [Abstract][Full Text] [Related]
8. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?
Senti G; von Moos S; Kündig TM
Allergy; 2011 Jun; 66(6):798-809. PubMed ID: 21518374
[TBL] [Abstract][Full Text] [Related]
9. Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials.
Senti G; Freiburghaus AU; Kundig TM
Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):582-6. PubMed ID: 20827178
[TBL] [Abstract][Full Text] [Related]
10. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections.
Senti G; Crameri R; Kuster D; Johansen P; Martinez-Gomez JM; Graf N; Steiner M; Hothorn LA; Grönlund H; Tivig C; Zaleska A; Soyer O; van Hage M; Akdis CA; Akdis M; Rose H; Kündig TM
J Allergy Clin Immunol; 2012 May; 129(5):1290-6. PubMed ID: 22464647
[TBL] [Abstract][Full Text] [Related]
11. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice.
Dioszeghy V; Mondoulet L; Dhelft V; Ligouis M; Puteaux E; Benhamou PH; Dupont C
J Immunol; 2011 May; 186(10):5629-37. PubMed ID: 21490160
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of subcutaneous allergen immunotherapy.
Soyer OU; Akdis M; Akdis CA
Immunol Allergy Clin North Am; 2011 May; 31(2):175-90, vii-viii. PubMed ID: 21530813
[TBL] [Abstract][Full Text] [Related]
13. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy.
Mondoulet L; Dioszeghy V; Ligouis M; Dhelft V; Dupont C; Benhamou PH
Clin Exp Allergy; 2010 Apr; 40(4):659-67. PubMed ID: 20002446
[TBL] [Abstract][Full Text] [Related]
14. Intralymphatic immunotherapy: from the rationale to human applications.
Senti G; Johansen P; Kündig TM
Curr Top Microbiol Immunol; 2011; 352():71-84. PubMed ID: 21725898
[TBL] [Abstract][Full Text] [Related]
15. [Innovative forms of specific immunotherapy].
Zieglmayer P
Hautarzt; 2017 Apr; 68(4):287-291. PubMed ID: 28197701
[TBL] [Abstract][Full Text] [Related]
16. Allergen-related approaches to immunotherapy.
Rolland JM; Gardner LM; O'Hehir RE
Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
[TBL] [Abstract][Full Text] [Related]
17. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence.
Calderón MA; Cox L; Casale TB; Moingeon P; Demoly P
J Allergy Clin Immunol; 2012 Apr; 129(4):929-34. PubMed ID: 22244595
[TBL] [Abstract][Full Text] [Related]
18. A review of allergy and allergen specific immunotherapy.
Bidad K; Nicknam MH; Farid R
Iran J Allergy Asthma Immunol; 2011 Mar; 10(1):1-9. PubMed ID: 21358009
[TBL] [Abstract][Full Text] [Related]
19. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
[TBL] [Abstract][Full Text] [Related]
20. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
Focke M; Swoboda I; Marth K; Valenta R
Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
